Human papillomavirus vaccines: Current issues & future

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 341-347

  Kawana, Kei ^a   Yasugi, Toshiharu ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cervical cancer; Hpv vaccines; Human papillomavirus (HPV)

Indexed keywords

PLACEBO; SGN 00101; TGA 4001; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; ZYC 101A;

CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG TARGETING; GYNECOLOGICAL EXAMINATION; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LACTOBACILLUS; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LOAD; WART VIRUS;

DEVELOPING COUNTRIES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 72649101989     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. zur Hausen H. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
2. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-9.
3. Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
4. Masumoto N, Fujii T, Ishikawa M, Mukai M, Ono A, Iwata T, et al. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. Gynecol Oncol 2004; 94: 509-14.
5. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. WHO, Geneva; February 16-18, 1999.
6. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
7. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9.
8. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8.
9. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24S1: S1/4-S1/15.
10. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-8.
11. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
12. Ochi H, Kondo K, Matsumoto K, Oki A, Yasugi T, Furuta R, et al. Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 2008; 15: 1536-40.
13. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.
14. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66.
15. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
16. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. FUTURE I investigators, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
17. FUTURE II study group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
18. Miura S, Matsumoto K, Oki A, Satoh T, Tsunoda H, Yasugi T, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006; 119: 2713-15.
19. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
20. Wright TC Jr. Current status of HPV vaccination recommendation. HPV Today 2008; 14: 8-9.
21. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Neutralizing epitope of L2 minor capsid protein common to human papillomavirus type 16 and 6. J Virol 1999; 73: 6188-90.
22. Kawana K, Yasugi T, Kanda T, Kino N, Oda K, Okada S, et al. Safety and immunogenicity of a peptide containing the cross- neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 2003; 21: 4256-60.
23. Kondo K, Ishii Y, Oshi H, Matsumoto T, Yoshikawa H, Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007; 358: 266-72.
24. th, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000; 270: 254-7.
25. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81: 11585-92.
26. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Pro Natl Acad Sci USA 2008; 105: 5850-5.
27. Slupetzky K, Gambhira R, Culp TD, Shafti-keramat S, Schellenbacher C, Christensen ND, et al. A papillomavirus- like particle (VLP. vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2007; 25: 2001-10.
28. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 2008; 80: 841-6.
29. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus- induced lesions. Int J Cancer 2008; 122: 247-59.
30. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
31. Kawana K, Yasugi T, Kanda T, Kawana Y, Hirai Y, Yoshikawa H, et al. Neutralizing antibodies against oncogenic human papillomavirus (HPV) as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun 2002; 296: 102-5.
32. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106: 453-60.
33. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007; 106: 558-66.
34. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007; 121: 2794-800.
35. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-41.
36. Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006; 16: 1075-81.
37. García-Hernández E, González-Sánchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13: 592-7.
38. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103: 317-26.
39. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175: 7297-302.
40. Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Patient K, Langella P, Bermúdez-Humarán LG. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007; 25: 6581-8.